An engineered insulin-like growth factor-1 analog. The Arg3 substitution sharply reduces affinity for IGF binding proteins, and the N-terminal extension further limits sequestration — so far more free peptide reaches the IGF-1 receptor, and potency and duration rise substantially versus native IGF-1. It is a laboratory reagent designed for cell culture, not a therapeutic.
Ubiquitous as a cell-culture supplement. There are no controlled human trials. Human use is entirely extrapolated from IGF-1 biology and anecdote.
Not FDA-approved. Sold as a laboratory reagent. Prohibited in sport (WADA S2).
The most acutely hazardous peptide in this library. IGF-1 receptor agonism produces insulin-like effects — severe hypoglycaemia is a real and rapid risk. IGF-1 signalling is mitogenic, and sustained elevation is epidemiologically associated with certain cancers. Cardiac and renal hypertrophy are documented in animal models.
Forge Bioenergy does not publish dosing, reconstitution, or administration protocols for any peptide. See our editorial policy for why. If you are considering any substance on this page, that conversation belongs with a licensed physician.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.